tert-butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4: Inhibition of cytochrome P450 catalysis by steric hindrance

Molecular Pharmacology

Volumn 76, Issue 5, 2009, Pages 1011-1018

  Zhang, Haoming ^a   Lin, Hsia Lien ^a   Walker, Vyvyca J ^a   Hamdane, Djemel ^b   Hollenberg, Paul F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 TERT BUTYLPHENYLACETYLENE; BENZPHETAMINE; CYTOCHROME P450 2B4; CYTOCHROME P450 REDUCTASE; DOCKING PROTEIN; ENZYME INHIBITOR; HEME; PHENYLACETYLENE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THREONINE; UNCLASSIFIED DRUG;

ABSORPTION SPECTROPHOTOMETRY; ANIMAL CELL; ARTICLE; BINDING SITE; CATALYSIS; CONTROLLED STUDY; COVALENT BOND; ELECTRON TRANSPORT; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INACTIVATION; ENZYME KINETICS; ENZYME SUBSTRATE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR MODEL; NONHUMAN; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PURIFICATION; STEADY STATE; STEREOSPECIFICITY; STOICHIOMETRY;

ACETYLENE; ARYL HYDROCARBON HYDROXYLASES; BENZPHETAMINE; CATALYSIS; CATALYTIC DOMAIN; PROTEIN BINDING; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 70350457938     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.059808     Document Type: Article

References (29)

1. Blobaum AL, Harris DL, and Hollenberg PF (2005) P450 active site architecture and reversibility: inactivation of cytochrome P450 2B4 and 2B4 T302A by tert-butyl acetylenes. Biochemistry 44:3831-3844.
2. Chan WK, Sui Z, and Ortiz de Montellano PR (1993) Determinants of protein modification versus heme alkylation: inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene. Chem Res Toxicol 6:38-45. (Pubitemid 23040370)
3. Davydov R, Macdonald ID, Makris TM, Sligar S, and Hoffman BM (1999) EPR and ENDOR of catalytic intermediates in cryoreduced native and mutant oxycytochromes P450cam: mutation-induced changes in the proton delivery system. J Am Chem Soc 121:10654-10655.
4. Davydov R, Makris TM, Kofman V, Werst DE, Sligar SG, and Hoffman BM (2001) Hydroxylation of camphor by reduced oxy-cytochrome P450cam: mechanistic implications of EPR and ENDOR studies of catalytic intermediates in native and mutant enzymes. J Am Chem Soc 123:1403-1415. (Pubitemid 32167333)
5. Denisov IG, Makris TM, Sligar SG, and Schlichting I (2005) Structure and chemistry of cytochrome P450. Chem Rev 105:2253-2277.
6. Gan LS, Acebo AL, and Alworth WL (1984) 1-Ethynylpyrene, a suicide inhibitor of cytochrome P-450 dependent benzo[a]pyrene hydroxylase activity in liver microsomes. Biochemistry 23:3827-3836. (Pubitemid 14002752)
7. Hamdane D, Zhang H, and Hollenberg P (2008) Oxygen activation by cytochrome P450 monooxygenase. Photosynth Res 98:657-666. (Pubitemid 50197788)
8. Hernandez CE, Kumar S, Liu H, and Halpert JR (2006) Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys 455:61-67. (Pubitemid 44754700)
9. Hollenberg PF, Kent UM, and Bumpus NN (2008) Mechanism-based inactivation of human cytochromes P450s: experimental characterization, reactive intermediates, and clinical implications. Chem Res Toxicol 21:189-205.
10. Imai Y, Sato R, and Iyanagi T (1977) Rate-limiting step in the reconstituted microsomal drug hydroxylase system. Journal of Biochemistry 82:1237-1246. (Pubitemid 8221866)
11. Kent UM, Bend JR, Chamberlin BA, Gage DA, and Hollenberg PF (1997) Mechanism- based inactivation of cytochrome P450 2B1 by N-benzyl-1- aminobenzotriazole. Chem Res Toxicol 10:600-608. (Pubitemid 27217218)
12. Kent UM, Juschyshyn MI, and Hollenberg PF (2001) Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr Drug Metab 2:215-243. (Pubitemid 32782795)
13. Kent UM, Lin HL, Mills DE, Regal KA, and Hollenberg PF (2006) Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6. Chem Res Toxicol 19:279-287.
14. Komives EA and Ortiz de Montellano PR (1987) Mechanism of oxidation of pi bonds by cytochrome P-450. Electronic requirements of the transition state in the turnover of phenylacetylenes. J Biol Chem 262:9793-9802.
15. Muralidhara BK, Negi S, Chin CC, Braun W, and Halpert JR (2006) Conformational flexibility of mammalian cytochrome P450 2B4 in binding imidazole inhibitors with different ring chemistry and side chains. Solution thermodynamics and molecular modeling. J Biol Chem 281:8051-8061. (Pubitemid 43847423)
16. Ortiz de Montellano P, and Kunze KL (1980) Occurrence of a 1,2 shift during enzymatic and chemical oxidation of a terminal acetylene. J Am Chem Soc 102: 7373-7375.
17. Ortiz de Montellano PR and Komives EA (1985) Branchpoint for heme alkylation and metabolite formation in the oxidation of arylacetylenes by cytochrome P-450. J Biol Chem 260:3330-3336.
18. Paul KG, Theorell H, and Akeson A (1953) The molar light absorption of pyridine ferroprotoporphyrin (pyridine haemochromogen). Acta Chem Scand 7:1284-1287.
19. Roberts ES, Alworth WL, and Hollenberg PF (1998) Mechanism-based inactivation of cytochromes P450 2E1 and 2B1 by 5-phenyl-1-pentyne. Arch Biochem Biophys 354:295-302.
20. Roberts ES, Hopkins NE, Zaluzec EJ, Gage DA, Alworth WL, and Hollenberg PF (1994) Identification of active-site peptides from 3H-labeled 2-ethynylnaphthalene- inactivated P450 2B1 and 2B4 using amino acid sequencing and mass spectrometry. Biochemistry 33:3766-3771.
21. Roberts ES, Hopkins NE, Zaluzec EJ, Gage DA, Alworth WL, and Hollenberg PF (1995) Mechanism-based inactivation of cytochrome P450 2B1 by 9-ethynylphenanthrene. Arch Biochem Biophys 323:295-302. (Pubitemid 28373980)
22. Scott EE, Spatzenegger M, and Halpert JR (2001) A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function. Arch Biochem Biophys 395:57-68. (Pubitemid 33030143)
23. Silverman RB (1995) Mechanism-based enzyme inactivators. Methods Enzymol 249: 240-283.
24. Vatsis KP, Oprian DD, and Coon MJ (1979) Kinetics of reduction of purified liver microsomal cytochrome P-450 in the reconstituted enzyme system studied by stopped flow spectrophotometry. Acta Biol Med Ger 38:459-473.
25. Wright AT, Song JD, and Cravatt BF (2009) A suite of activity-based probes for human cytochrome P450 enzymes. J Am Chem Soc 131:10692-10700.
26. Zhang H, Gruenke L, Arscott D, Shen A, Kasper C, Harris DL, Glavanovich M, Johnson R, and Waskell L (2003) Determination of the rate of reduction of oxyferrous cytochrome P450 2B4 by 5-deazariboflavin adenine dinucleotide T491V cytochrome P450 reductase. Biochemistry 42:11594-11603. (Pubitemid 37243619)
27. Zhang H, Hamdane D, Im SC, and Waskell L (2008) Cytochrome b5 inhibits electron transfer from NADPH-cytochrome P450 reductase to ferric cytochrome P450 2B4. J Biol Chem 283:5217-5225.
28. Zhang H, Kenaan C, Hamdane D, Hui Bon Hoa G and Hollenberg P (2009) Effect of conformational dynamics on substrate recognition and specificity as probed by the introduction of a de novo disulfide bond into cytochrome P450 2B1. J Biol Chem doi:10.1074/jbc.M109.032748.
29. Zhao Y, White MA, Muralidhara BK, Sun L, Halpert JR, and Stout CD (2006) Structure of microsomal cytochrome P450 2B4 complexed with the antifungal drug bifonazole: insight into P450 conformational plasticity and membrane interaction. J Biol Chem 281:5973-5981. (Pubitemid 43847698)